PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase as a Therapeutic Strategy for Cancer.
作者信息
Kargbo Robert B
机构信息
Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.
出版信息
ACS Med Chem Lett. 2021 Apr 12;12(5):688-689. doi: 10.1021/acsmedchemlett.1c00178. eCollection 2021 May 13.
Abstract
摘要
相似文献
1
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase as a Therapeutic Strategy for Cancer.PROTAC介导的布鲁顿酪氨酸激酶降解作为癌症治疗策略
ACS Med Chem Lett. 2021 Apr 12;12(5):688-689. doi: 10.1021/acsmedchemlett.1c00178. eCollection 2021 May 13.
2
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.布鲁顿酪氨酸激酶抑制剂对急性心肌梗死患者血小板聚集的影响。
Thromb Res. 2019 Jul;179:64-68. doi: 10.1016/j.thromres.2019.04.024. Epub 2019 Apr 24.
3
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.利用PROTAC介导的降解作用靶向布鲁顿酪氨酸激酶中的C481S依鲁替尼耐药突变
Biochemistry. 2018 Jul 3;57(26):3564-3575. doi: 10.1021/acs.biochem.8b00391. Epub 2018 Jun 14.
4
PROTAC for Bruton's tyrosine kinase degradation alleviates inflammation in autoimmune diseases.用于降解布鲁顿酪氨酸激酶的PROTAC可减轻自身免疫性疾病中的炎症。
Cell Discov. 2024 Aug 6;10(1):82. doi: 10.1038/s41421-024-00711-x.
5
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.用于BTK的蛋白酶靶向嵌合体可有效抑制B细胞受体信号传导，并能克服慢性淋巴细胞白血病（CLL）细胞中的依鲁替尼耐药性。
Front Oncol. 2021 May 13;11:646971. doi: 10.3389/fonc.2021.646971. eCollection 2021.
6
Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia.布鲁顿酪氨酸激酶结构域的晶体结构揭示了一种新的激活途径，并为X连锁无丙种球蛋白血症的分子基础提供了见解。
J Biol Chem. 2001 Nov 2;276(44):41435-43. doi: 10.1074/jbc.M104828200. Epub 2001 Aug 29.
7
Targeting spleen tyrosine kinase-Bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis.针对免疫介导性肾小球肾炎的脾酪氨酸激酶-Bruton 酪氨酸激酶轴。
Biomed Res Int. 2014;2014:814869. doi: 10.1155/2014/814869. Epub 2014 Mar 30.
8
Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.基于哌啶基二吡咯并吡啶的 Janus 激酶和布鲁顿酪氨酸激酶双重抑制剂的开发：一种治疗类风湿关节炎的潜在治疗可能性。
J Mol Model. 2020 Aug 17;26(9):235. doi: 10.1007/s00894-020-04512-3.
9
Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.布鲁顿酪氨酸激酶抑制用于类风湿关节炎的治疗
Immunotargets Ther. 2021 Aug 28;10:333-342. doi: 10.2147/ITT.S288550. eCollection 2021.
10
Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.布鲁顿酪氨酸激酶抑制剂在霍奇金淋巴瘤细胞和皮下肿瘤模型中的临床前抗肿瘤活性
Heliyon. 2019 Aug 31;5(8):e02290. doi: 10.1016/j.heliyon.2019.e02290. eCollection 2019 Aug.
引用本文的文献
1
FDA-approved kinase inhibitors in PROTAC design, development and synthesis.FDA批准的用于PROTAC设计、开发和合成的激酶抑制剂。
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2542357. doi: 10.1080/14756366.2025.2542357. Epub 2025 Aug 12.
2
Stabilized Carbon Radical-Mediated Assembly of Arylthianthrenium Salts, Alkenes and Amino Acid/Peptide Derivatives.稳定碳自由基介导的芳基噻蒽鎓盐、烯烃与氨基酸/肽衍生物的组装
Adv Sci (Weinh). 2025 Jan;12(2):e2411579. doi: 10.1002/advs.202411579. Epub 2024 Nov 21.
3
Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies.酪氨酸激酶抑制剂靶向治疗的耐药机制及克服策略。
MedComm (2020). 2024 Aug 24;5(9):e694. doi: 10.1002/mco2.694. eCollection 2024 Sep.
4
Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review.炎症介导和自身免疫靶点中PROTACs开发的最新见解：一项批判性综述。
RSC Med Chem. 2024 May 8;15(8):2585-2600. doi: 10.1039/d4md00142g. eCollection 2024 Aug 14.
5
An overview of PROTACs: a promising drug discovery paradigm.蛋白水解靶向嵌合体（PROTACs）概述：一种前景广阔的药物发现模式。
Mol Biomed. 2022 Dec 20;3(1):46. doi: 10.1186/s43556-022-00112-0.
6
Discovery of E3 Ligase Ligands for Target Protein Degradation.E3 连接酶配体用于靶蛋白降解的发现。
Molecules. 2022 Oct 2;27(19):6515. doi: 10.3390/molecules27196515.
本文引用的文献
1
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.布鲁顿酪氨酸激酶抑制剂的药物相互作用：临床意义与管理。
Cancer Chemother Pharmacol. 2020 Oct;86(4):507-515. doi: 10.1007/s00280-020-04137-6. Epub 2020 Sep 17.
2
Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors.布鲁顿酪氨酸激酶（Btk）抑制剂对新冠病毒病血栓炎症的选择性抑制作用
Platelets. 2020 Nov 16;31(8):989-992. doi: 10.1080/09537104.2020.1809647. Epub 2020 Sep 6.
3
A Fast and Clean BTK Inhibitor.一种快速且清洁的 BTK 抑制剂。
J Med Chem. 2020 May 28;63(10):5100-5101. doi: 10.1021/acs.jmedchem.0c00597. Epub 2020 May 13.
4
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).在感染 COVID-19 的癌症患者中使用 BTK 抑制剂：“胜者将是那个能控制住混乱局面的人”（拿破仑·波拿巴）。
Clin Cancer Res. 2020 Jul 15;26(14):3514-3516. doi: 10.1158/1078-0432.CCR-20-1427. Epub 2020 Apr 28.
5
Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.新兴布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病：伊布替尼更进一步。
Expert Opin Emerg Drugs. 2020 Mar;25(1):25-35. doi: 10.1080/14728214.2020.1724282. Epub 2020 Feb 6.
Zotero 插件